Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. operates as a global diversified pharmaceutical company with business segments spanning gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. News related to Bausch Health may cover developments across any of these therapeutic areas, including product approvals, clinical trial results, regulatory actions, and commercial launches. The company's Salix business unit focuses on gastroenterology products, with particular emphasis on treatments for hepatic encephalopathy, irritable bowel syndrome, and other gastrointestinal conditions.
Corporate news may include updates on the company's debt management strategies, as Bausch Health has historically carried significant debt obligations stemming from acquisitions. Financial reporting typically addresses performance across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Bausch + Lomb eye health business represents a substantial portion of company operations and may generate independent news flow regarding vision care products, contact lenses, ophthalmic pharmaceuticals, and surgical equipment.
Dermatology news through the Ortho Dermatologics business may cover new acne treatments, psoriasis therapies, and other prescription dermatology products. Aesthetic medicine developments from Solta Medical often involve non-invasive cosmetic treatment technologies. Strategic acquisitions represent a key component of Bausch Health's growth strategy, with the company periodically acquiring businesses with complementary products in core therapeutic areas. Patent litigation and intellectual property matters frequently impact pharmaceutical companies, and Bausch Health may face generic competition for key products as patents expire.
Regulatory filings, including SEC reports, clinical trial registrations, and FDA submissions, provide transparency into company operations and pipeline developments. Investors monitor revenue trends across business segments, particularly the gastroenterology franchise which includes high-value products. Generic pharmaceutical competition, international market performance, and research and development progress all contribute to the ongoing narrative around this diversified pharmaceutical enterprise.
Bausch Health (NYSE:BHC) announced final results and expiration of exchange offers for its outstanding 4.875% and 11.00% Senior Secured Notes due 2028. The offers expired on December 23, 2025. Holders validly tendered an aggregate of $2.7 billion of existing notes; the Offerors accepted existing notes resulting in approximately $1.6 billion principal amount of new 10.00% Senior Secured Notes due 2032, with settlement currently expected on December 26, 2025. The New Notes are unregistered in the U.S. and Canada and will be issued pursuant to the exchange terms described in the exchange offer memorandum.
Bausch Health (NYSE:BHC) announced early results of exchange offers to swap its outstanding 4.875% and 11.00% senior secured notes due 2028 for up to $1.6 billion aggregate principal of new 10.00% senior secured notes due 2032 issued by subsidiary 1261229 B.C. Ltd.
As of 5:00 p.m. ET on December 8, 2025, holders validly tendered $2,690,016,000 of existing notes, and the company expects to issue approximately $1,600 million of New Notes after applying the Maximum Notes Amount and proration. The Withdrawal Deadline passed on December 8; the Offers expire at 5:00 p.m. ET on December 23, 2025, with settlement expected within three business days after expiration.
Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., the Shibo group's aesthetics distribution business, effective December 1, 2025. The Shibo group, a distribution partner for more than a decade, becomes a wholly owned Solta Medical subsidiary in China and assumes full responsibility for distributing Solta Medical products, including Thermage FLX.
The transaction is intended to deepen local presence, provide direct customer insight, speed market execution, and support growing demand for aesthetic treatments in China.
Bausch Health (NYSE:BHC) commenced offers on November 24, 2025 to exchange up to $1.6 billion aggregate principal of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032 issued by a wholly owned subsidiary.
Key terms: Exchange Consideration per $1,000 is $787.50 (4.875% notes) and $920.00 (11.00% notes); an Early Exchange Premium $100 per $1,000 applies for tenders by Dec 8, 2025; offers expire Dec 23, 2025. New Notes will be fungible with the issuer's existing 10.00% notes due 2032 and are subject to eligibility, customary conditions and a transaction support agreement covering ~$1,545 million of existing notes.
Bausch Health (NYSE:BHC) said Jean-Jacques Charhon, executive vice president and chief financial officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025.
The session is scheduled for 10:50 a.m. – 11:10 a.m. ET and a live audio webcast will be available via the company’s Investor Relations website at http://ir.bauschhealth.com/events-and-presentations. A replay will be posted on the investor site after the event.
Bausch Health (NYSE:BHC) and its dental business OraPharma announced commercial expansion of Arestin into Canada and Puerto Rico on November 5, 2025, aiming to improve access to periodontal disease treatments and strengthen distributor and dental professional partnerships.
Arestin is described as the only FDA‑approved locally applied antibiotic for use with scaling and root planing and is supported by over 20 years of clinical experience. The release highlights high regional disease prevalence and includes safety and prescribing information for Arestin.
Bausch Health (NYSE:BHC) reported third quarter 2025 consolidated revenue of $2.68 billion, up 7% year-over-year (5% organic), GAAP net income attributable to Bausch Health of $179 million, and consolidated adjusted EBITDA (non-GAAP) of $986 million (includes an $81 million acquired IPR&D charge).
Key operational highlights: tenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth excluding Bausch + Lomb; completed acquisition of DURECT and added Larsucosterol with FDA Breakthrough Therapy Designation; redeemed ~$601 million of 9.25% notes and repaid a $300 million receivables facility post-quarter. Company raised full-year 2025 revenue and adjusted EBITDA guidance.
Bausch Health (NYSE: BHC) announced that shareholders approved the Amended and Restated Shareholder Rights Plan Agreement at a special meeting held on October 7, 2025. The Rights Plan is dated April 14, 2025 and was amended and restated on August 25, 2025. The company said the final vote tabulation will be filed with the U.S. SEC on a Form 8-K and will be available on SEDAR+ and the company website.
This notice confirms shareholder ratification, and indicates the company will publicly report the detailed vote results via regulatory and company channels.
Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, will be featured on Lifetime TV's The Balancing Act, showcasing its portfolio of non-invasive skin rejuvenation technologies. The segment will spotlight three key products: Thermage® FLX for skin tightening using radiofrequency technology, Clear + Brilliant® Touch for early aging signs treatment, and Fraxel FTX™ for addressing fine lines and scars.
The program, hosted by Montel Williams and Olga Villaverde, will air on October 2 and October 24, 2025, featuring demonstrations and expert insights from dermatologists. The segment will be available on multiple streaming platforms including Sling TV, Hulu, Live, and Fubu.
Bausch Health (NYSE:BHC) has scheduled its third quarter 2025 financial results announcement for October 29, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update.
All presentation materials will be available on the company's Investor Relations website before the call begins. A replay of the conference call will also be accessible through the investor relations website at ir.bauschhealth.com.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
